PHOTO
Riyadh, KSA - Roche, the biotechnology leader, announced today that it has received its license to operate from the General Investment Authority (SAGIA) for its diagnostics division as a joint venture with local distributor Farouk, Maamoun Tamer & Co. during His Excellency Governor Ibrahim Al Omar, Director of SAGIA, visit to Roche’s headquarters in Basel, Switzerland on the 14th of September 2018. This important milestone grants Roche the opportunity to expand its local diagnostics operations and footprint in the market, as it establishes its legal entity in the Kingdom.
Commenting on this occasion and how this milestone aligns with the company’s strategy in serving patients and partners in the Middle East, Dr. Christoph Franz, Chairman of the Board at Roche, said: “We are thrilled to embark on this new journey in the Kingdom of Saudi Arabia, especially at a time where the country is on the cusp of a positive change.”
This growing commitment by the Swiss leader in KSA will allow for greater investments into education and employment opportunities for local talent to develop and grow in and outside the country, a shared purpose mirrored in the ambitions of the Kingdom’s Vision 2030. Harald Wolf, General Manager at Roche Diagnostics Middle East, said: “We are pleased to strengthen our presence in the Kingdom and be closer to our patients and partners. Our mission remains unwavered as we aim to have our innovations accessible for every patient who needs them. After all, our ground-breaking advances in medical science are only meaningful when they reach the people who need them, and this is why our expansion into the Kingdom is an incredibly successful milestone.”
On his part, Dr. Ali Al Watban, Head of Roche Diagnostics in KSA welcomed this decision and “the great impact this achievement has for patients in the Kingdom who need diagnostics to lead healthier lives”. “We want to be able to support healthcare professionals as much as possible, to make accurate and reliable clinical decisions. We are doing just that by bringing in the latest diagnostic innovations to the Kingdom. Time is critical when it comes to the lives of members of the community and we need to increase patient access to the latest devices as fast as possible”, he added.
Roche has established a legal entity for its pharmaceutical division in 2016 which has also brought the company one step closer to patients of the Kingdom in need for the latest groundbreaking medicines. The biotech multi-national also has a strong presence in the diabetes care sector in the Kingdom through a partnership with a local distributor.
-Ends-
About Roche Diagnostics Middle East (RDME):
RDME has taken the unprecedented move of being the first IVD Company to have a Management Centre and a logistics hub in the Middle East. RDME has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region. This base of operations reinforces the commitment to global Roche standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services. With this regional empowerment, RDME has moved its leadership and decision-making closer to its customers and distributors. These investments allow Roche Diagnostics Middle East to develop from being a supplier into becoming the preferred IVD partner for its customers.
RDME offers a complete portfolio of services in 16 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, Egypt, Libya and Maldives. For more information, please visit www.roche-middleeast.com.
For press inquiries, please contact:
Maysoun Ramadan
Head of Communications & Public Affairs – Middle East
Roche Diagnostics Middle East
maysoun.ramadan@roche.com
Stephanie Tasrini
Asda’a Burson-Marsteller
stephanie.tasrini@bm.com
© Press Release 2018Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
